New biologic aims to quiet the itch of a chronic skin condition
NCT ID NCT07704775
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether nemolizumab, an injectable biologic, can reduce severe itching in women with vulvar lichen sclerosus, a chronic inflammatory skin condition. Participants receive weight-based doses of the drug and track their itch scores daily. The study focuses on symptom relief rather than curing the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nemolizumab, an injectable biologic drug
- What this could lead to
- If successful, this could offer a new treatment option for severe itching in lichen sclerosus, especially for those who don't respond well to steroid creams.
- What could go wrong
- This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. The drug may not prove effective or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LICHEN SCLEROSUS OF VULVA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.